80
Participants
Start Date
August 31, 2013
Primary Completion Date
December 31, 2015
Study Completion Date
December 31, 2015
Dovitinib (TKI258)
Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.
St. Agnes Hospital St. Agnes Hospital (2), Baltimore
Virginia Cancer Specialists Virginia Cancer Specialists, Fairfax
Waverly Hematology Oncology, Cary
Gibbs Cancer Center & Research Institute Spartanburg Reg. Healthcare, Spartanburg
NorthWest Georgia Oncology Centers NW Georgia Oncology, Marietta
University Cancer & Blood Center, LLC, Athens
Cancer Specialists of North Florida Cancer Specialists (2), Jacksonville
Space Coast Medical Associates Space Coast Cancer Center, Titusville
Florida Hospital Cancer Institute, Orlando
Memorial Cancer Institute Memorial Healthcare System, Hollywod
Alabama Oncology, Birmingham
Sarah Cannon Research Institute Tennessee Oncology, Nashville
Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology, Chattanooga
The West Clinic, Memphis
Cleveland Clinic Foundation Cleveland Clinic (19), Cleveland
Oncology Hematology Care, Inc. Oncology Hematology Care (2), Cincinnati
Indiana University Indiana Univ. - Purdue Univ., Indianapolis
Horizon Oncology Center Horizon Oncology Ctr., Lafayette
University of Michigan Int. Medicine Oncology, Ann Arbor
Aurora Research Institute, Milwaukee
Medical College of Wisconsin Cancer Ctr.-Froedtert Hospital, Milwaukee
Minnesota Oncology Hematology, P.A. Minnesota Oncology Hematology, Minneapolis
Billings Clinic Onc Dept, Billings
Lurie Children's Hospital of Chicago Developmental Therapeutics, Chicago
Southeast Nebraska Oncology Cancer Center, Lincoln
Highlands Oncology Group SC, Fayetteville
Texas Oncology Texas Oncology - Sammons, Dallas
Texas Oncology Midtown Texas Oncology, Dallas
Tyler Cancer Center, Tyler
The Center for Cancer and Blood Disorders, Fort Worth
Oncology Consultants Oncology Group, Houston
MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3), Houston
Austin Cancer Centers Austin Cancer Center (2), Austin
Intermountain Medical Center Intermountain Healthcare, Murray
Comprehensive Cancer Centers of Nevada CCC of Nevada- Southwest (2), Las Vegas
Sarcoma Oncology Center, Santa Monica
PCR Oncology, Pismo Beach
Oregon Health & Science University OHSU Knight Cancer Institute, Portland
St. Charles Cancer Center, Bend
Providence Regional Cancer Partnership Providence Reg. Cancer (2), Everett
Northwest Medical Specialties Hematology/Oncology, Tacoma
Wenatchee Valley Medical Center Wenatchee Valley, Wenatchee
Yakima Valley Memorial Hospital North Star Lodge Cancer Center, Yakima
Evergreen Hematology & Oncology, Spokane
Rocky Mountain Cancer Centers Rocky Mountain Cancer Centers, Greenwood Village
Whittingham Cancer Center Norwalk Hospital, Norwalk
Illinois Cancer Care, Peoria
University of Pittsburgh Cancer Institute, Pittsburgh
Rhode Island Hospital Rhode Island Hosp. (2), Providence
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY